Improving the fate of severely infected patients: the promise of anti-toxin treatments and superiority trials

November 1, 2017
Combioxin SA

Severe infections requiring immediate admission to special units in hospital, and involving intravenous antibiotics and supportive therapy such as fluids or vasopressors, are still associated with unacceptably high mortality rates. A retrospective overview, spanning the past decade, of the performance of new antibiotics is dismaying indeed. Novel approaches and new regulatory paths to develop treatments that will significantly improve the fate of severely infected patients are urgently needed.

Download Editorial